Sign in
Active, not recruitingPhase 1

A study to investigate a potential effect of rilzabrutinib (SAR444671) on ethinylestradiol and levonorgestrel from combined oral contraceptives in healthy female participants

Key facts

Who runs it
Sanofi-Aventis Recherche & Developpement
Where
Germany1 site in 1 countryChoose a country to see its sites
Status
Active, not recruiting
Phase
Phase 1
People taking part
24 people, planned
Started
30 Jun 2026
Expected to end
31 Dec 2026
Type of study
Interventional
Record updated
20 October 2026

Who can take part

Age
18 years to 64 years
Sex
Women only
Healthy volunteers
Can take part

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
20 October 2026